30 September 2016 - - Timothy Barberich has been appointed to US-based biopharmaceutical company Inotek Pharmaceuticals Corp.'s (NASDAQ: ITEK) board of directors, the company said.

He will serve as head of the compensation committee.

Barberich founded Sepracor Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, and served as chairman and chief executive officer for over 20 years.

Under his leadership, Sepracor commercialized and partnered several products, including Allegra, Brovana, Clarinex, Lunesta and Xopenex. Before founding Sepracor, Barberich was a senior executive at Millipore Corp.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialisation of therapies for glaucoma and other eye diseases.

The company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. 

Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism.

Additionally, the company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases.